PU.1-dependent enhancer inhibition separates Tet2-deficient hematopoiesis from malignant transformation Journal Article


Authors: Aivalioti, M. M.; Bartholdy, B. A.; Pradhan, K.; Bhagat, T. D.; Zintiridou, A.; Jeong, J. J.; Thiruthuvanathan, V. J.; Pujato, M.; Paranjpe, A.; Zhang, C.; Levine, R. L.; Viny, A. D.; Wickrema, A.; Verma, A.; Will, B.
Article Title: PU.1-dependent enhancer inhibition separates Tet2-deficient hematopoiesis from malignant transformation
Abstract: Cytosine hypermethylation in and around DNA-binding sites of master transcription factors, including PU.1, occurs in aging hematopoietic stem cells following acquired loss-of-function mutations of DNA methyl-cytosine dioxygenase ten-eleven translocation-2 (TET2), albeit functional relevance has been unclear. We show that Tet2-deficient mouse hematopoietic stem and progenitor cells undergo malignant transformation upon compromised gene regulation through heterozygous deletion of an upstream regulatory region (URE delta/WT) of the PU.1 gene. Although compatible with multilineage blood formation at young age, Tet2-deficient PU.1 URE delta/WT mice develop highly penetrant, transplantable acute myeloid leukemia (AML) during aging. Leukemic stem and progenitor cells show hypermethylation at putative PU.1-binding sites, fail to activate myeloid enhancers, and are hallmarked by a signature of genes with impaired expression shared with human AML. Our study dem-onstrates that Tet2 and PU.1 jointly suppress leukemogenesis and uncovers a methylation-sensitive PU.1-dependent gene network as a unifying molecular vulnerability associated with AML. SIGNIFICANCE: We identify moderately impaired PU.1 mRNA expression as a biological modality pre-disposing Tet2-deficient hematopoietic stem and progenitor cells to malignant transformation. Our study furthermore uncovers a methylation-sensitive PU.1 gene network as a common feature of myeloid leukemia potentially allowing for the identification of patients at risk for malignant transformation.
Keywords: age; targets; mutations; gene-expression; stem-cells; acute myeloid-leukemia; tet2; transcription factor pu.1; clonal hematopoiesis; cell-development
Journal Title: Blood Cancer Discovery
Volume: 3
Issue: 5
ISSN: 2643-3230
Publisher: American Association for Cancer Research  
Date Published: 2022-09-01
Start Page: 444
End Page: 467
Language: English
ACCESSION: WOS:000855133200001
DOI: 10.1158/2643-3230.Bcd-21-0226
PROVIDER: wos
PUBMED: 35820129
PMCID: PMC9894728
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ross Levine
    778 Levine